

INDGN/SE/2025-26/99

January 29, 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

**Sub: Press Release**

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the copy of Press Release dated January 29, 2026, titled "Indegene Reports Strong Q3 FY26 Performance with 30%+ YoY Revenue Growth".

Kindly take the same on records.

Thanking you,

Yours Sincerely,  
**For Indegene Limited**

**Srishti Ramesh Kaushik**  
**Company Secretary and Compliance Officer**

Encl: As above



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy  
Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-  
560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777  
[www.indegene.com](http://www.indegene.com)

CIN: L73100KA1998PLC102040

## Press release

# Indegene Reports Strong Q3 FY26 Performance with 30%+ YoY Revenue Growth

**Bengaluru, India, January 29, 2026:** Indegene, the tech-native, life sciences specialist, announced its financial results for the quarter ended December 31, 2025.

- Achieved revenue of INR 9,421 million, reflecting 30.8% growth YoY & 17.1% growth QoQ
- Maintained a strong profitability profile, with an adjusted EBITDA of INR 1,747 million, growing 15.7% YoY & 19.6% QoQ. Adjusted EBITDA margin of 18.5% expanded 30bps from the previous qtr.
- We crossed a few key milestones in Q3:
  - First \$ 100+ million quarterly revenue
  - Revenue per employee (RPE) crossing \$70k - the highest in the industry
  - 3 of top 5 customers have expanded to \$25 million+ p.a.
  - 52 customers with \$1 million + annual revenue
- Significant new marquee deal wins with 2 customer contracts exceeding \$10 million ACV each across 5 work orders and another exceeding \$5 million ACV (\$20 million TCV) across 2 work orders

Sl. No.	Particulars	Quarter ended		
		Dec 31, 2025	Sep 30, 2025	Dec 31, 2024
1.	Revenue from operations	9,421	8,042	7,204
2.	Revenue from operations (\$ Mn)	106.1	92.2	85.2
3.	YoY revenue growth from operations (%)	30.8%	17.1%	7.0%
4.	Adjusted EBITDA <sup>(1)</sup>	1,747	1,461	1,511
5.	Adjusted EBITDA margin <sup>(1)</sup> (%)	18.5%	18.2%	21.0%
6.	Profit after tax	1,026	1,021	1,097
7.	Profit margin (%)	10.9%	12.7%	15.2%

<sup>(1)</sup> EBITDA is adjusted to exclude non-operating one-time expenses

“We delivered a standout Q3 FY26, with revenue growing over 30% YoY and 17% sequentially, marking it the first \$100 million+ revenue quarter. Our revenue per employee has crossed the \$70K annual mark - the highest in the industry - underscoring the tangible impact of technology and AI in scaling productivity”, said Manish Gupta, Chairman and CEO, Indegene. “This quarter, 3 customers surpassed the \$25 million annual revenue milestone, and 52 customers exceeded the \$1 million annual level, reinforcing the depth of our client relationships. We also secured several breakthrough wins, where clients are partnering with us to combine our proven execution strength with AI to transform their operations and unlock differentiated, measurable outcomes. This momentum positions Indegene well to continue delivering sustained, profitable growth over the long term.”

“During the quarter, we completed the acquisitions of BioPharm, a US-focused life sciences omnichannel business, and Warn & Co., a UK-based consulting firm - both strategically important additions that deepen our domain expertise and expand our high-value capabilities. Our cash and investments are a healthy INR 13,954 million, net of acquisition outflows, with continued cash generation strengthening our balance sheet. EBITDA adjusted for one-time expenses, rose to Rs. 1,747 million, growing 15.7% YoY and 19.6% sequentially”, said Suhas Prabhu, CFO, Indegene. “While reported PAT remained flat at Rs. 1,026 million this quarter, due to one-time expenses and higher non-cash amortization, these impacts are transient. As integration synergies are realized, acquisition-related costs taper off, and growth momentum continues, we expect profitability to continue to strengthen, supporting further EPS expansion.”



## About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is the tech-native, life sciences specialist orchestrating the path from commercialization strategy through execution. Trusted by the world's top 20 biopharma companies across the value chain - from clinical and medical through commercial - Indegene helps life sciences leaders move at the speed of their ambition with #PractitionerLevelConfidence. Indegene's difference comes from integrating deep domain knowledge, contextualized technology and operational excellence, built over 25 years. When bold life sciences leaders want to take breakthrough therapies to market faster, maximize impact, and create seamless experiences for patients and physicians, they count on Indegene. Orchestrate your path at [www.indegene.com](http://www.indegene.com)

For Investor inquiries, please contact:  
IR@Indegene.com

For media inquiries, please contact:  
Yadunandan K V | yadunandan.kv@indegene.com